VYNE
Vyne Therapeutics Inc
NASDAQ: VYNE · HEALTHCARE · BIOTECHNOLOGY
$0.67
+0.53% today
Updated 2026-05-06
Market cap
$21.39M
P/E ratio
—
P/S ratio
37.52x
EPS (TTM)
$-0.63
Dividend yield
—
52W range
$0 – $2
Volume
0.2M
Vyne Therapeutics Inc (VYNE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-4,015.00%
ROE
-67.00%
ROA
-38.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2015 | — | $-4.61M | — | — | — |
| 2016 | $674000.00 | $-14.07M | 100.00% | -2,126.41% | -2,087.24% |
| 2017 | $4.58M | $-29.08M | 100.00% | -645.85% | -634.57% |
| 2018 | $10.64M | $-51.45M | 100.00% | -512.55% | -483.51% |
| 2019 | $1.75M | $-70.46M | 5.31% | -4,356.69% | -4,026.51% |
| 2020 | $20.99M | $-255.57M | 93.37% | 1,203.00% | -1,217.40% |
| 2021 | $931000.00 | $-73.33M | 100.00% | -4,179.48% | -7,876.37% |
| 2022 | $477000.00 | $-23.21M | 100.00% | -7,189.73% | -4,865.83% |
| 2023 | $424000.00 | $-28.45M | 100.00% | -6,900.47% | -6,710.38% |
| 2024 | $501000.00 | $-39.83M | 100.00% | -8,709.98% | -7,950.90% |
| 2025 | $570000.00 | $-26.48M | 95.96% | -5,219.12% | -4,646.14% |